These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20420125)

  • 21. Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis?
    Sidoti A; Antognelli C; Rinaldi C; D'Angelo R; Dattola V; Girlanda P; Talesa V; Amato A
    Mult Scler; 2007 May; 13(4):446-53. PubMed ID: 17463067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy of multiple sclerosis: where are we? Where should we go?
    Martin R; Stürzebecher CS; McFarland HF
    Nat Immunol; 2001 Sep; 2(9):785-8. PubMed ID: 11526386
    [No Abstract]   [Full Text] [Related]  

  • 23. The genetic influence of the nonclassical MHC molecule HLA-G on multiple sclerosis.
    Kroner A; Grimm A; Johannssen K; Mäurer M; Wiendl H
    Hum Immunol; 2007 May; 68(5):422-5. PubMed ID: 17462509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Demonstration of T-cell and K-cell cytotoxicity against measles-infected cells in normal subjects, multiple sclerosis and subacute sclerosing panencephalitis.
    Ewan PW; Lachmann PJ
    Clin Exp Immunol; 1977 Oct; 30(1):22-31. PubMed ID: 304777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple sclerosis: circulating antigen-reactive lymphocytes.
    Traugott U; Scheinberg LC; Raine CS
    Ann Neurol; 1979 Nov; 6(5):425-9. PubMed ID: 92911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Role of immunoregulatory cells and natural killers in the pathogenesis of multiple sclerosis].
    Tunkel' OI; Saidov MZ; Cheredeev AN; Koval'chuk LV; Skriabina EG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(6):880-5. PubMed ID: 6224384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunological aspects of multiple sclerosis].
    Miyagishi R; Fukaura H; Fukazawa T; Tashiro K
    No To Shinkei; 1993 Oct; 45(10):917-24. PubMed ID: 8268031
    [No Abstract]   [Full Text] [Related]  

  • 28. Progression of multiple sclerosis is associated with exon 1 CTLA-4 gene polymorphism.
    Bilińska M; Frydecka I; Noga L; Dobosz T; Zołedziewska M; Suwalska K; Tutak A; Pokryszko-Dragan A
    Acta Neurol Scand; 2004 Jul; 110(1):67-71. PubMed ID: 15180809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potassium channels, memory T cells, and multiple sclerosis.
    Beeton C; Chandy KG
    Neuroscientist; 2005 Dec; 11(6):550-62. PubMed ID: 16282596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunogenetic aspects of neuroimmunologic diseases].
    Meyer-Rienecker HJ; Hitzschke B; Wegener S; Jenssen HL
    Z Arztl Fortbild (Jena); 1983; 77(1):7-12. PubMed ID: 6845759
    [No Abstract]   [Full Text] [Related]  

  • 31. [Interferon-producing and cytotoxic activity of natural killer cells in multiple sclerosis patients].
    Sorokin AM; Koval'chuk LV; Tunkel' OI; Cheknev SB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1987; 87(2):211-5. PubMed ID: 2437743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cells and microglia as drivers of multiple sclerosis pathology.
    Friese MA; Fugger L
    Brain; 2007 Nov; 130(Pt 11):2755-7. PubMed ID: 17956912
    [No Abstract]   [Full Text] [Related]  

  • 33. Neuroimmunology I: Immunoregulation in neurological disease.
    Weiner HL; Hauser SL
    Ann Neurol; 1982 May; 11(5):437-49. PubMed ID: 6179458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
    Racke MK; Lovett-Racke AE; Karandikar NJ
    Neurology; 2010 Jan; 74 Suppl 1():S25-30. PubMed ID: 20038760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The autoimmune disease-associated IL12B and IL23R polymorphisms in multiple sclerosis.
    Begovich AB; Chang M; Caillier SJ; Lew D; Catanese JJ; Wang J; Hauser SL; Oksenberg JR
    Hum Immunol; 2007 Nov; 68(11):934-7. PubMed ID: 18082575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KIR2DL4 (CD158d) polymorphisms and susceptibility to multiple sclerosis.
    Goris A; Dobosi R; Boonen S; Nagels G; Dubois B
    J Neuroimmunol; 2009 May; 210(1-2):113-5. PubMed ID: 19304328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-mediated immunity in neurologic disease.
    Zweiman B; Lisak RP
    Hum Pathol; 1986 Mar; 17(3):234-45. PubMed ID: 3005157
    [No Abstract]   [Full Text] [Related]  

  • 38. [Multiple sclerosis and regulatory cells].
    Yamamura T; Takahashi K; Araki M
    Nihon Rinsho; 2005 May; 63 Suppl 5():422-6. PubMed ID: 15954386
    [No Abstract]   [Full Text] [Related]  

  • 39. Enumeration of T, B and natural killer peripheral blood cells of patients with multiple sclerosis and controls.
    Kreuzfelder E; Shen G; Bittorf M; Scheiermann N; Thraenhart O; Seidel D; Grosse-Wilde H
    Eur Neurol; 1992; 32(4):190-4. PubMed ID: 1505587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural killing activity and interferon production in multiple sclerosis.
    Zander H; Abb J; Kaudewitz P; Riethmüller G
    Lancet; 1982 Jan; 1(8266):280. PubMed ID: 6173558
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.